Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
16 Outubro 2023 - 9:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker
as Executive Vice President, Chief Financial Officer. Mr. Parker
will oversee the Company’s financial operations and business
strategy and will serve as a member of the Leadership Team.
“Geoff’s extensive experience in biotechnology across all
aspects of finance and business development strategy will be of
tremendous value to Allogene as we advance our critical pipeline
assets and explore new opportunities,” said David Chang, M.D.,
Ph.D., President, Chief Executive Officer and Co-Founder of
Allogene. “Geoff’s commitment to excellence aligns perfectly with
Allogene’s vision for the future, and I am confident he’ll be
instrumental as we advance one of the most important modalities in
cancer treatment.”
Mr. Parker is a seasoned biotech and banking executive with
nearly 40 years of leadership experience managing world-class
finance and business development organizations. He has directed and
managed a broad range of strategic business and finance
initiatives, including equity and debt financing, initial public
offerings, and business development transactions.
“I am excited to join Allogene during this pivotal time in the
company’s evolution,” said Mr. Parker. “My focus will be on
continuing its legacy of operational excellence through the lens of
financial stewardship, and I look forward to being a part of
Allogene as we work to expand access to CAR T for patients in
need.”Before joining Allogene, Mr. Parker served as Chief Operating
Officer, Chief Financial Officer and Executive Vice President of
Tricida, Inc., which focused on the development of an
investigational drug candidate for metabolic acidosis in patients
with chronic kidney disease. Prior to that, Mr. Parker served as
Chief Financial Officer of Anacor Pharmaceuticals, which was
acquired by Pfizer in 2016 for approximately $5.2 billion, and
served as a Managing Director at Goldman Sachs, where he led the
West Coast Healthcare Investment Banking group. In addition, Mr.
Parker currently serves as a member of the board of directors of
Better Therapeutics and of Perrigo Company plc. Mr. Parker earned a
B.A. with a double major in Economics and Engineering Sciences from
Dartmouth College and an MBA from the Stanford Graduate School of
Business.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T cell candidates with the goal of delivering readily available
cell therapy on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com and
follow @AllogeneTx on X (formerly Twitter) and
LinkedIn.Cautionary Note on Forward-Looking
Statements This press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as “advance,” "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could,"
"might," "will," "should" or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Forward-looking statements include statements regarding
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things Allogene’s ability to
develop and deliver readily available allogeneic CAR T products for
cancer treatment on-demand, more reliably, and at greater scale to
more patients. Various factors may cause material differences
between Allogene’s expectations and actual results, including risks
and uncertainties related to: our product candidates are based on
novel technologies, which makes it difficult to predict the time
and cost of product candidate development and obtaining regulatory
approval; the extent to which the FDA disagrees with our
clinical or regulatory plans, which could cause future delays to
our clinical trials or require additional clinical trials; we may
not be able to demonstrate the safety and efficacy of our product
candidates in our clinical trials, which could prevent or delay
regulatory approval and commercialization; and our ability to
obtain additional financing to develop our products and implement
our operating plans. These and other risks are discussed in greater
detail in Allogene’s filings with the SEC, including without
limitation under the “Risk Factor” Heading in its Form 10-Q filed
for the quarter ended June 30, 2023. Any forward-looking statements
that are made in this press release speak only as of the date of
this press release. Allogene assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Corporate Affairs and Brand Strategy
OfficerChristine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Allogene Therapeutics (NASDAQ:ALLO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024